• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Virogates

10.20 DKK

0.00 %

Less than 1K followers

VIRO

First North Denmark

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
0.00 %
-5.56 %
-3.77 %
-21.54 %
-24.16 %
+18.60 %
-41.73 %
-92.03 %
-84.53 %

Virogates is active in medical technology. The company is active in research and development of biomarkers and diagnostic instruments for the healthcare industry. The products are sold under various brands and are used in the identification, analysis and further treatment of diseases, primarily cardiovascular diseases, cancer and neurological diseases. The company was established in 2001 and is headquartered in Birkerød.

Read more
Market cap
94.7M DKK
Turnover
2.25K DKK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
20.8.
2026

Interim report Q2'26

5.11.
2026

Interim report Q3'26

All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release07.05.2026 klo 14.12

ViroGates announces its Interim Report for Q1-2026

Virogates
Regulatory press release23.04.2026 klo 21.15

Resolutions from the Annual General Meeting of ViroGates A/S

Virogates
Regulatory press release08.04.2026 klo 23.37

ViroGates submits its De Novo application to the U.S. FDA for suPARnostic® TurbiLatex

Virogates

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release08.04.2026 klo 17.19

ViroGates gives notice to convene the Annual General Meeting on 23 April 2026

Virogates
Regulatory press release26.03.2026 klo 16.10

ViroGates announces its Annual Report 2025: Revenue growth and improved operating result as strategic transition towards preventive health and longevity continues

Virogates
Regulatory press release12.12.2025 klo 13.15

ViroGates publishes its financial calendar for 2026

Virogates
Regulatory press release12.12.2025 klo 12.33

ViroGates announces financial guidance for 2026

Virogates
Regulatory press release28.11.2025 klo 16.39

ViroGates’ capital raise of DKK 19.3 million and issue of 1,547,412 shares have been registered and settled

Virogates
Regulatory press release20.11.2025 klo 15.30

suPAR Remedy, LLC announces the Completion of the public tender offer to the shareholders of ViroGates.

Virogates
Regulatory press release18.11.2025 klo 08.41

ViroGates announces a directed issue of nominally 1,547,412 shares, raising approximately DKK 19.3 million

Virogates
Regulatory press release18.11.2025 klo 00.31

ViroGates announces a plan to offer new shares through a directed issue without preemptive rights for existing shareholders

Virogates
Regulatory press release12.11.2025 klo 09.40

suPAR Remedy, LLC announces the outcome of the Public Tender Offer to the shareholders of ViroGates.

Virogates
Regulatory press release06.11.2025 klo 14.34

ViroGates announces its Interim Report for Q1-Q3 2025

Virogates
Regulatory press release23.10.2025 klo 16.29

ViroGates announces Notice of Potential Equity / Capital Raise

Virogates
Regulatory press release17.10.2025 klo 15.36

ViroGates Receives FDA Feedback on 513(g) Request, confirming Regulatory Pathway for U.S. Market Entry

Virogates
Regulatory press release15.10.2025 klo 16.22

ViroGates announces the publication of a Board Statement in relation to the Tender Offer from suPAR Remedy, LLC

Virogates
Regulatory press release10.10.2025 klo 09.52

ViroGates announces the receipt of an Announcement and Official Tender Offer Document from suPAR Remedy LLC

Virogates
Regulatory press release08.10.2025 klo 09.53

suPAR Remedy, LLC announces public tender offer to the shareholders of ViroGates A/S at a 40% premium

Virogates
Regulatory press release21.08.2025 klo 12.25

ViroGates announces its Half-Year Report for H1 2025

Virogates
Press release16.06.2025 klo 16.30

ViroGates and GENSPEED achieve proof of concept for their suPARnostic® POC+ targeted at the Longevity Testing Market

Virogates